Amyloid generation and dysfunctional immunoproteasome activation with disease progression in animal model of familial Alzheimer's disease. - Wikidata - awgldk - TriplyDB

Amyloid generation and dysfunctional immunoproteasome activation with disease progression in animal model of familial Alzheimer's disease.

Amyloid generation and dysfunctional immunoproteasome activation with disease progression in animal model of familial Alzheimer's disease.

http://www.wikidata.org/entity/Q48762970

about

Olfactory Receptors in Non-Chemosensory Organs: The Nervous System in Health and Disease Age- and Brain Region-Specific Changes of Glucose Metabolic Disorder, Learning, and Memory Dysfunction in Early Alzheimer's Disease Assessed in APP/PS1 Transgenic Mice Using 18F-FDG-PET.Immunoproteasome deficiency alters microglial cytokine response and improves cognitive deficits in Alzheimer's disease-like APPPS1 mice.The ubiquitin-proteasome system in neurodegenerative diseases: precipitating factor, yet part of the solution Inhibitory effect of b-AP15 on the 20S proteasome Amyloid and tau pathology of familial Alzheimer's disease APP/PS1 mouse model in a senescence phenotype background (SAMP8).Time dynamics of protein complexes in the AD11 transgenic mouse model for Alzheimer's disease like pathology.Docosahexaenoic (DHA) modulates phospholipid-hydroperoxide glutathione peroxidase (Gpx4) gene expression to ensure self-protection from oxidative damage in hippocampal cells Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease Intravenous ascorbate improves spatial memory in middle-aged APP/PSEN1 and wild type mice.The Proteasome and Oxidative Stress in Alzheimer's Disease.Addition of docosahexaenoic acid, but not arachidonic acid, activates glutathione and thioredoxin antioxidant systems in murine hippocampal HT22 cells: potential implications in neuroprotection.Lipid Raft Size and Lipid Mobility in Non-raft Domains Increase during Aging and Are Exacerbated in APP/PS1 Mice Model of Alzheimer's Disease. Predictions from an Agent-Based Mathematical Model.Altered mechanisms of protein synthesis in frontal cortex in Alzheimer disease and a mouse model.An integrated proteomics approach shows synaptic plasticity changes in an APP/PS1 Alzheimer's mouse model.Genotype-induced changes in biophysical properties of frontal cortex lipid raft from APP/PS1 transgenic mice.The cerebellum in Alzheimer's disease: evaluating its role in cognitive decline.Sisyphus in Neverland.Fibrinogen-Derived γ377-395 Peptide Improves Cognitive Performance and Reduces Amyloid-β Deposition, without Altering Inflammation, in AβPP/PS1 Mice.Evidence for premature lipid raft aging in APP/PS1 double-transgenic mice, a model of familial Alzheimer disease.Mid-life environmental enrichment increases synaptic density in CA1 in a mouse model of Aβ-associated pathology and positively influences synaptic and cognitive health in healthy ageing.Brain energy metabolism and neuroinflammation in ageing APP/PS1-21 mice using longitudinal 18F-FDG and 18F-DPA-714 PET imaging.AβPP/PS1 Transgenic Mice Show Sex Differences in the Cerebellum Associated with Aging.Reactive glia show increased immunoproteasome activity in Alzheimer's disease.Hippocampal Lipid Homeostasis in APP/PS1 Mice is Modulated by a Complex Interplay Between Dietary DHA and Estrogens: Relevance for Alzheimer's Disease.Impact of Neurodegenerative Diseases on Drug Binding to Brain Tissues: From Animal Models to Human Samples.Age-Related Increase of Insulin-Degrading Enzyme Is Inversely Correlated with Cognitive Function in APPswe/PS1dE9 Mice.Huatuo Zaizao pill ameliorates cognitive impairment of APP/PS1 transgenic mice by improving synaptic plasticity and reducing Aβ deposition.Induction of the Immunoproteasome Subunit Lmp7 Links Proteostasis and Immunity in α-Synuclein Aggregation Disorders.Dopaminergic neurons show increased low-molecular-mass protein 7 activity induced by 6-hydroxydopamine in vitro and in vivo

P2860

Q26741605-4AE516D7-DB80-4BA5-9015-526BFF887174 Q31138018-15467AC2-7CF9-481C-B159-4D4B6E3E7C2C Q33831029-EB26C8BB-0444-49C2-80FD-50B5D7630264 Q33980214-FE1A3352-4C55-41A3-8697-DBCE608D9090 Q34785773-B882317E-9302-4331-8CEB-48E457735CC3 Q35058977-88073258-4A7D-4BF6-BC92-CB34549425D2 Q35618276-63945F4A-041E-4640-B82B-808D4FC1AA7B Q35878063-16E112BF-5667-4AF4-BF8E-D010ADC06CCB Q36756941-34D9D093-CDFB-4997-B9C0-ABEA87FADEF2 Q37693458-524DCE3C-CD7E-4C10-A35D-4A22505FF023 Q38843876-31A1D69D-823F-42DA-A6AB-AC52285CCA98 Q38933785-302285C7-6155-43E7-8029-4A7CC5B06430 Q38994779-AA9F9876-5C4A-465D-8DC2-C8E0D3208D82 Q40955570-54A0BCCF-EBCA-4481-B738-98C20BA8A837 Q41609863-269D8D93-053D-4720-91D0-6575C31186FF Q42355559-0AE122F7-D12B-46E6-826C-3A152C7569F6 Q47592930-1AB17276-DA33-48C4-B625-4ABDEB49767F Q47607995-901DE855-073B-49F5-9A53-1C83999537B9 Q47612205-00A80ADB-3AE9-4FCF-BA34-C0DFB3DB971F Q48377897-5A708933-CA98-475A-A512-3CF5C261D551 Q48392464-F84F1D32-B963-4989-83E4-FBA588F43624 Q48433741-6A15DF49-15EC-41A4-B7D7-1E29EA5FB82F Q48547364-E637DA5B-56C6-4CAA-9229-925762A09ED7 Q51055475-1F7A363C-90F6-4D02-BF40-235905FBA5D2 Q52147336-8CA9F8D3-F2B1-4EB3-BE7A-67B25C728099 Q53397308-85D211EE-FA70-4FE2-B1BE-1DAFB02B3B7C Q55253035-AC10A1A4-9121-429F-8020-BBDA7107BB9F Q55262808-BECE4977-1D3B-424A-94C9-D2931EBD41B2 Q55305758-36154B10-CC8D-4771-89A0-6BF6A5259C94 Q58771881-2D399EEA-AD1A-4843-ACB3-F8B3FC02CA5B

P2860

Amyloid generation and dysfunctional immunoproteasome activation with disease progression in animal model of familial Alzheimer's disease.

http://www.wikidata.org/entity/Q48762970

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Amyloid generation and dysfunc ...... familial Alzheimer's disease.

@en

Amyloid generation and dysfunc ...... familial Alzheimer's disease.

@nl

type

label

Amyloid generation and dysfunc ...... familial Alzheimer's disease.

@en

Amyloid generation and dysfunc ...... familial Alzheimer's disease.

@nl

prefLabel

Amyloid generation and dysfunc ...... familial Alzheimer's disease.

@en

Amyloid generation and dysfunc ...... familial Alzheimer's disease.

@nl

P1433

Q48762970-AD3300A5-BA25-4ADB-AA93-847EF75E8D25

P1476

Q48762970-EEA7DF2C-219C-43C8-A0CF-86E2DD7BF7E2

P2093

Q48762970-03945821-3278-4382-B3E3-456D63696C2D

Q48762970-0D758D12-1BE3-4249-9FE1-271EF006FBCF

Q48762970-0F95065E-0A7D-481D-B44C-D75574C7DCD3

Q48762970-41627F93-52B6-49D4-9323-B8F07D591B58

Q48762970-471B5961-9666-4DEB-986F-4C573B949693

Q48762970-5024A3F2-F51B-48FB-B7A3-B01EF65056D9

Q48762970-5E849E04-01FA-4833-B372-396B0B14DE62

Q48762970-AA78350E-8ACE-48AE-8DBD-3BAFEAAFD771

Q48762970-C917F94B-A981-49A0-B919-44A2ADE3273F

Q48762970-DFBB0A91-9358-4FDE-8F65-A45B0DE18E29

P2860

Q48762970-05E13B74-69C8-4A70-B884-ECE6BF08AF85

Q48762970-0C8CF5EF-B3D1-4676-B40E-C904429DFB5B

Q48762970-122A3AA8-2FE2-43D3-85F8-2F66928D577E

Q48762970-153712DF-3797-448D-88B0-42D5EF4C3024

Q48762970-18F1C582-8F1D-4788-81D9-1D2566EB2BC2

Q48762970-1E293453-6A6D-4AB5-8013-8A8597022C74

Q48762970-23C558AB-FD78-460E-AD47-679CD34F19A1

Q48762970-3697AA3E-0130-487D-9CCE-5B44930A7E0B

Q48762970-36EEF10B-D367-4B8D-A2E6-900423E02DE1

Q48762970-3D8F1BBC-586A-401A-87C0-4737143D054F

P304

Q48762970-35951F76-7B30-45A3-8556-186683711A9E

P31

Q48762970-864FB4C6-140A-42F6-9008-0FAFB2CC948A

P356

Q48762970-CE09E795-BCAF-4E73-8364-A65B055004F8

P433

Q48762970-59638369-D68E-4885-9503-35A681CA9D94

P478

Q48762970-EF7577B2-B850-428A-8558-1E47293625FE

P50

Q48762970-68372A65-B94A-48F9-8B80-BBE5C1FD916A

Q48762970-75F657EB-73C4-4026-B7DA-83857329FB48

Q48762970-D7530F8D-12FE-4AB4-91CC-B691C0012949

Q48762970-E859A579-FE42-485C-AA97-8786A769E864

P577

Q48762970-1410BE2E-C1EE-413A-A086-A18C35F9A847

P5875

Q48762970-0678EA12-A10A-4C28-97B1-E2BBC7E67CC9

P698

Q48762970-5A864B55-164B-46E0-9B06-1E1E761DE076

P921

Q48762970-7227C53B-BB00-433A-BBC7-26B2174992BF

P356

J.1750-3639.2011.00560.X

P1433

Brain Pathology

P1476

Amyloid generation and dysfunc ...... familial Alzheimer's disease.

@en

P2093

Irene López-González

http://www.w3.org/2001/XMLSchema#string

Isidro Ferrer

http://www.w3.org/2001/XMLSchema#string

Jesús Moreno

http://www.w3.org/2001/XMLSchema#string

Laura Joda

http://www.w3.org/2001/XMLSchema#string

Manuel Portero-Otin

http://www.w3.org/2001/XMLSchema#string

Margarita Carmona

http://www.w3.org/2001/XMLSchema#string

Núria Fernández-Yagüe

http://www.w3.org/2001/XMLSchema#string

Salvador Juvés

http://www.w3.org/2001/XMLSchema#string

Selene Lomoio

http://www.w3.org/2001/XMLSchema#string

Virginia Martín

http://www.w3.org/2001/XMLSchema#string

P2860

The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction

Neurotoxicity of Alzheimer's disease Aβ peptides is induced by small changes in the Aβ42 to Aβ40 ratio

Substrate binding and catalysis by ubiquitin C-terminal hydrolases: identification of two active site residues

Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients

The ubiquitin system

The ubiquitin-proteasome system in Alzheimer's disease

Early growth response 1 (Egr-1) regulates phosphorylation of microtubule-associated protein tau in mammalian brain

A beta oligomers - a decade of discovery

The 26S proteasome: a molecular machine designed for controlled proteolysis

Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred.

P304

636-653

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1750-3639.2011.00560.X

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

Reinald Pamplona

P577

2012-01-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230546791

http://www.w3.org/2001/XMLSchema#string

P698

22188425

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease